200 related articles for article (PubMed ID: 35247914)
21. Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Jagadeeshan S; Prasad M; Badarni M; Ben-Lulu T; Liju VB; Mathukkada S; Saunders C; Shnerb AB; Zorea J; Yegodayev KM; Wainer M; Vtorov L; Allon I; Cohen O; Gausdal G; Friedmann-Morvinski D; Cheong SC; Ho AL; Rosenberg AJ; Kessler L; Burrows F; Kong D; Grandis JR; Gutkind JS; Elkabets M
Cancer Res; 2023 Apr; 83(7):1031-1047. PubMed ID: 36753744
[TBL] [Abstract][Full Text] [Related]
22. Effect of photodynamic therapy on expression of HRAS, NRAS and caspase 3 genes at mRNA levels, apoptosis of head and neck squamous cell carcinoma cell line.
Yousefi M; Koopaie M; Karimi R; Kermani FM; Kolahdooz S; Shamshiri A
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102142. PubMed ID: 33307231
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.
Broutian TR; Jiang B; Li J; Akagi K; Gui S; Zhou Z; Xiao W; Symer DE; Gillison ML
Cancer Lett; 2020 Apr; 476():23-33. PubMed ID: 31958486
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
25. [Farnesyltransferase inhibitors have antitumoral effects in mutant KRAS containing cancer cells in preclinical models].
Baranyi M; Hegedűs B; Molnár E; Tóvári J; Ranđelović I; Perczel A; Buday L; Keserű G; Tímár J
Magy Onkol; 2023 Sep; 67(3):223-235. PubMed ID: 38484318
[TBL] [Abstract][Full Text] [Related]
26. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
27. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV
Brand TM; Hartmann S; Bhola NE; Peyser ND; Li H; Zeng Y; Isaacson Wechsler E; Ranall MV; Bandyopadhyay S; Duvvuri U; LaVallee TM; Jordan RCK; Johnson DE; Grandis JR
Clin Cancer Res; 2017 Jun; 23(12):3072-3083. PubMed ID: 27986750
[No Abstract] [Full Text] [Related]
28. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
29. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
30. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
31. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
33. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
[TBL] [Abstract][Full Text] [Related]
34. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Chen X; Makarewicz JM; Knauf JA; Johnson LK; Fagin JA
Oncogene; 2014 Nov; 33(47):5442-9. PubMed ID: 24240680
[TBL] [Abstract][Full Text] [Related]
35. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
Geryk-Hall M; Yang Y; Hughes DP
Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
[TBL] [Abstract][Full Text] [Related]
36. Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck.
Sasaki E; Masago K; Fujita S; Hanai N; Yatabe Y
J Pathol Clin Res; 2020 Apr; 6(2):154-159. PubMed ID: 31960612
[TBL] [Abstract][Full Text] [Related]
37. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
38. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
39. Correlate the
Lyu H; Li M; Jiang Z; Liu Z; Wang X
Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
